血清miR-30a水平与乳腺癌化疗敏感性的相关性  

Correlation between serum miR-30a level and chemosensitivity of breast cancer

作　　者：曹蓉 杜阿妮 CAO Rong;DU Ani(Laboratory Department,Xi'an Gaoxin Hospital,Shaanxi Xi'an 710075,China.)

机构地区：[1]西安高新医院检验科,陕西西安710075

出　　处：《现代肿瘤医学》2021年第14期2468-2471,共4页Journal of Modern Oncology

摘　　要：目的:探讨血清miR-30a水平对局部进展期乳腺癌患者新辅助化疗敏感性的预测价值。方法:纳入145例TNM分期为Ⅱ-Ⅲ期乳腺癌患者,根据实体瘤疗效评价标准(RECIST 1.0)将患者分为化疗敏感组(103例)和化疗抵抗组(42例),通过实时荧光定量PCR检测患者初次化疗前血清miR-30a水平,并与健康人群进行比较。通过受试者工作特征曲线(receiver operating characteristic, ROC)确定血清miR-30a对化疗抵抗的预测价值和阈值,并分析化疗抵抗相关的独立危险因素。结果:与化疗敏感患者相比,化疗抵抗组中年龄大于40岁、T分期为T3-4期、TNM分期为Ⅲ期患者比例更高,差异存在统计学意义(P<0.05)。化疗敏感组患者血清miR-30a水平显著低于健康对照组(0.79±0.21 vs 1.24±0.36,P=0.004),而化疗抵抗组患者血清miR-30a水平则低于化疗敏感组患者(0.34±0.12 vs 0.79±0.21,P<0.001)。ROC曲线分析显示血清miR-30a对化疗抵抗的预测阈值为0.48,灵敏度81.2%,特异度76.5%,并且化疗抵抗组中血清miR-30a≤0.48的患者比例显著高于敏感组(71.4%vs 25.2%,P<0.001)。多因素logistics回归分析显示,血清miR-30a≤0.48(OR=1.982,95%CI:1.672~2.583,P<0.001)、TNM分期Ⅲ期(OR=1.604,95%CI:1.123~2.084,P=0.001)是预测乳腺癌患者化疗抵抗的独立危险因素。结论:血清miR-30a水平能够有效预测局部进展期乳腺癌患者新辅助化疗疗效,有望成为预测乳腺癌化疗敏感性的有效生物标志物。Objective:To investigate the predictive value of serum miR-30 a level for neoadjuvant chemotherapy in patients with locally advanced breast cancer.Methods:145 breast cancer patients with TNM Ⅱ-Ⅲ stage were enrolled.Patients were divided into chemotherapy-sensitive group(103 cases) and chemotherapy-resistant group(42 cases) according to the Response Evaluation Criteria in Solid Tumors(RECIST 1.0).Serum miR-30 a levels were measured by quantitative real-time PCR before initial chemotherapy and compared with healthy controls.The predictive value and threshold of serum miR-30 a for chemotherapy resistance were determined by receiver operating characteristic(ROC),and independent risk factors related to chemotherapy resistance were analyzed.Results:Compared with chemotherapy-sensitive patients, the proportion of patients older than 40 years, T3-4 stage, and TNM III stage was higher in the chemotherapy-resistant group, with the statistically significant differences(P<0.05).The serum miR-30 a level in the chemotherapy-sensitive group was significantly lower than healthy control group(0.79±0.21 vs 1.24±0.36,P=0.004),while the serum miR-30 a level in the chemotherapy-resistant group was lower than chemotherapy-sensitive group(0.34±0.12 vs 0.79±0.21,P<0.001).ROC analysis showed that the predicted threshold of serum miR-30 a for chemotherapy resistance was 0.48,with the sensitivity of 81.2% and specificity of 76.5%.The proportion of patients with serum miR-30 a≤0.48 in the chemotherapy-resistant group was significantly higher than sensitive group(71.4% vs 25.2%,P<0.001).Multivariate logistic regression analysis showed that serum miR-30 a≤0.48(OR=1.982,95%CI:1.672~2.583,P<0.001),TNM Ⅲ stage(OR=1.604,95%CI:1.123~2.084,P=0.001) were independent risk factors for predicting chemotherapy resistance in breast cancer patients.Conclusion:Serum miR-30 a level can effectively predict the efficacy of neoadjuvant chemotherapy in patients with locally advanced breast cancer, and it is expected to be an effective biomarker fo

关 键 词：乳腺癌 局部进展期 新辅助化疗 微小RNA 

分 类 号：R737.9[医药卫生—肿瘤]